Navigation Links
More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals

Drugs meant for treatment of Attention Deficit Hyperactivity Disorder (ADHD), Ritalin (Novartis AG) and Adderall (Shire Pharmaceuticals) would be subjected to stringent clinical trials to assess the safety and side effects // of the drug.

The decision has been taken following the reports of the U.S. advisory panel, which stated that strong warnings should be associated with marketing of such drugs. There is a possibility of sudden death, heart attacks and other complications associated with the use of the drug.

The company officials have expressed keen interest in evaluating the relationship between these drugs and cardiovascular risk, taking into consideration the physicians and affected patients. The company would also support disclosure of all information, including the warning statement.

Data from the prospective clinical trial is believed to be very crucial in deciding whether the drug should carry a black box warning. The black box warning is issue to a prescription drug that is related to dangerous side effects. When surveyed, 7 of the 8 panel members recommended a black box warning for the drug.

The drug Adderall, marketed by Shire already carries a black box warning, highlighting the possibility of sudden death or cardiovascular complications. More than 1 million ADHD prescriptions are being written for adults while children receive nearly 2 million prescriptions every year.

The ADHD drugs closely resemble amphetamines in chemical composition, known to cause hypertension, a significant predisposing factor for heart disease. With more clinical trials being planned, it would not be long before the safety of Adderall can be established.


Page: 1

Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:

(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
(Date:6/24/2016)... D.C. (PRWEB) , ... June 24, 2016 , ... ... Heroes Golf Classic Tournament held on June 20th at the Woodmont Country Club ... charity, Luke’s Wings, an organization dedicated to helping service members that have been wounded ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: